Biology

Stem Cell Therapy Market- Roadmap for Recovery from COVID-19 | Increase in Awareness of Stem Cell Therapy to boost the Market Growth | Technavio

Friday, September 18, 2020 - 11:00pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Increase in awareness of stem cell therapy is one of the major factors driving the market.
  • The increase in awareness of stem cell therapy will offer immense growth opportunities.
  • Stem Cell Therapy Market 2020-2024: Segmentation
    Stem Cell Therapy Market is segmented as below:

World Market Outlook for the Regenerative Medicine Market to 2025 with Focus on Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

Friday, September 18, 2020 - 8:30pm

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Market Analysis & Forecast to 2025; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Market Analysis & Forecast to 2025; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report has been added to ResearchAndMarkets.com's offering.
  • Regenerative medicine's main objective is to heal and replace organs/cells that have been damaged by age, trauma or disease.
  • To that end, regenerative medicine is a broader field and manipulates the body's immune system and regeneration potential to achieve its requirement.
  • An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.

Meso Numismatics Update On Global Stem Cells Group Acquisition

Friday, September 18, 2020 - 8:30pm

We are close to submitting our past due filings with the SEC and now, with this payment, one step closer in completing the acquisition of Global Stem Cells Group, said David Christensen, CEO and President of the Company.

Key Points: 
  • We are close to submitting our past due filings with the SEC and now, with this payment, one step closer in completing the acquisition of Global Stem Cells Group, said David Christensen, CEO and President of the Company.
  • We maintain our continued optimism for the opportunities that Global Stem Cell Group brings to Stem Cell Bio Technology and the future that GSCG will play in Regenerative Medicine.
  • For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
    About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean.
  • Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Friday, September 18, 2020 - 8:04pm

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit onTuesday,September 22, 2020at2:30 p.m.

Key Points: 
  • NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit onTuesday,September 22, 2020at2:30 p.m.
  • The webcast will be available in the Events and Presentations section of the Company's website at ir.prevailtherapeutics.com .
  • Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases.
  • Prevail was founded by Dr.Asa Abeliovichin 2017, through a collaborative effort withThe Silverstein Foundationfor Parkinsons with GBA and OrbiMed, and is headquartered inNewYork, NY.

Global Cytogenetics Companies, Technologies, Markets, 2019-2020 & Estimates for 2024 and 2029

Friday, September 18, 2020 - 5:15pm

Markets figure are given for the year 2019 and estimates are made for the years 2024 and 2029.

Key Points: 
  • Markets figure are given for the year 2019 and estimates are made for the years 2024 and 2029.
  • The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH.
  • Molecular cytogenetics includes the applicationS of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection.
  • Microarray/biochip-based technologies for cytogenetics promise to speed up the detection of chromosome aberrations now examined by FISH.

Global CRISPR & Cas Genes Market Size, Share & Trends Analysis Report 2020-2027: Focus on Vector-based Cas, DNA-free Cas, Cell Line Engineering - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:09pm

The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes market size is expected to reach USD 4.88 billion by 2027, expanding at a CAGR of 16.6% from 2020 to 2027.
  • Rise in the adoption of CRISPR technology in epigenetics, therapeutics, human germline editing, plant genome editing, and other fields of biotechnology is expected to drive the market.
  • Presence of a large number of service providers that provide knockout, knock-in, gene repression, gene activation, and other cell line engineering services propel the growth of cell line engineering services.

Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics

Friday, September 18, 2020 - 12:05pm

On the basis of these positive data, the company also announced its rebranding to OncXerna Therapeutics, Inc., a change that reinforces the companys focus on using its RNA-based approach to guide novel, targeted treatments to specific people with cancer.

Key Points: 
  • On the basis of these positive data, the company also announced its rebranding to OncXerna Therapeutics, Inc., a change that reinforces the companys focus on using its RNA-based approach to guide novel, targeted treatments to specific people with cancer.
  • The trial is continuing to enroll both groups with planned updates from all patients during the first half of 2021.
  • These data are being presented at the European Society for Molecular Oncology (ESMO) Virtual Congress 2020 taking place September 19-21, 2020.
  • OncXerna plans to conduct additional clinical trials designed to prospectively enrich for TME Panel-1 biomarker positive patients, as well as to explore additional solid tumor types.

Global RNAi Report 2020: Focus on Technologies, Markets & Companies 2018-2028 - ResearchAndMarkets.com

Friday, September 18, 2020 - 11:01am

The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.
  • The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials.
  • We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Electroporation Instruments Market and Competitive Landscape & Pandemic Recovery Analysis 2020 - Technavio

Friday, September 18, 2020 - 12:15am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200917005676/en/
    Technavio has announced its latest market research report titled Global Electroporation Instruments Market 2020-2024 (Graphic: Business Wire)
    The research is classified into seven sections electroporation instruments market landscape, market sizing, five force analysis, customer landscape, geographic landscape, drivers, challenges, and trends, and vendor landscape and analysis.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    Electroporation Instruments Vendors: Identify key vendors of the electroporation instruments market, including company-revenue, market presence, influence-index, vendor-classification, and market positioning.
  • Electroporation Instruments Region Growth: Find out the highest and slowest growth of regions for electroporation instruments market.
  • Electroporation Instruments Market Valuations: Find out the global market size for electroporation instruments in 2019 and how the market will advance from 2020 to 2024.

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

Thursday, September 17, 2020 - 9:05pm

The move rounds out QIAGENs portfolio of automated molecular testing solutions based on the proven PCR technology.

Key Points: 
  • The move rounds out QIAGENs portfolio of automated molecular testing solutions based on the proven PCR technology.
  • The transaction was completed after QIAGEN received U.S. regulatory clearance for the full acquisition.
  • In 2018, QIAGEN had purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million.
  • The full integration of the NeuMoDx systems will allow QIAGEN to address laboratory needs in almost any setting for molecular diagnostics.